Home
My Account
About Us
Forum
Contact us
الواجهة العربية
epharmaweb.com
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz
Newsletter

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »



Zavedos

Main

You must sign in to use this servcie


Feedback - Please use the form below to send your query or comment

You must sign in to use this servcie

Username:
Password:

Info

Indications:

Acute non-lymphocytic leukaemia (ANLL), including acute myeloblastic leukaemia (AML) in adults, for remission induction as front-line therapy, or for remission induction in relapsed or refractory patients. The capsules are to be used when the intravenous route is not considered suitable.

Contraindications:

Severe renal and liver impairment. Patients with uncontrolled infections. Pre-existing bone marrow suppression induced by previous drug therapy or radiotherapy. Hypersensitivity to idarubicin and/or other anthracyclines. The use of idarubicin during pregnancy or lactation should be avoided. There is no information as to whether idarubicin may adversely affect human fertility or cause teratogenesis. However, in rats (but not in rabbits) it is teratogenic and embryotoxic and women of childbearing potential should be advised to avoid pregnancy while undergoing treatment.

Adverse reactions:

Major side-effects: Severe myelosuppression, prolonged bone marrow depression and cardiac toxicity. Other side-effects: Reversible alopecia, nausea and vomiting, mucositis, oesophagitis, diarrhoea, fever, chills and skin rash. Anorexia, stomatitis, phlebitis, fatigue, hyperglycaemia, headache, dysphagia, neurotoxicity and haemorrhage. Elevation of liver enzymes and bilirubin. Severe and sometimes fatal sepsis/infections have been associated with idarubicin as single agent or in combination. The urine may be coloured red. Severe enterocolitis with perforation has been reported very rarely.

Interactions:

Other myelosuppressants

Warnings:

Therapy with idarubicin requires close observation of the patient and laboratory monitoring. Hyperuricaemia may be induced. Appropriate measures must be taken to control any systemic infection before starting therapy.

Form:

Injecton

Dosage and Administration

You must sign in to use this servcie

Technical Description

You must sign in to use this servcie






Forgot your password


sign up

Consultants Corner

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Dr. Talal Sabouni

Dr. Talal Sabouni UROLOGY AND KIDNEY TRANSPLANT

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery

Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology
Poll

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details